WS #13278
AstraZeneca explored acquiring Bristol Myers Squibb in a $400B megadeal, but market skepticism about value creation persists.
AstraZeneca-BMS merger talks
AstraZeneca explored acquiring Bristol Myers Squibb in a $400B megadeal, but market skepticism about value creation persists.